“Combination Cancer Immunotherapy and New Immunomodulatory Targets” published in Nature Reviews Drug Discovery

4-1BB, cancer, CD27, CTLA4, GITR, IDO, immunotherapy, ipilimumab, lirilumab, MEDI4736, monoclonal antibodies, MPDL3280A, News, nivolumab, oncology, OX40, PD-1, PD-L1, pembrolizumab, T regulatory cells, TAMs, TGFbeta, TIGIT, TIM-3, TNF receptors, tumor microenvironment

The SugarCone Blog is brought to you by SugarCone Biotech Consulting - Click to learn more about what we can do for your company.

Part of the Article Series from Nature Reviews Drug Discovery, our paper hit the press today

Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery 14, 561–584. 2015.  doi:10.1038/nrd4591

by Kathleen Mahoney, Paul Rennert, Gordon Freeman.

a prepublication version is available here: nrd4591 (1)